Latest News
Riff Raff’s ‘Black Rabbit’ adds Morgan Spector to cast
Riff Raff Entertainment produced Netflix limited series Black Rabbit adds a new cast member Morgan Spector.
Riff Raff Entertainment (RRE), a film and television production company, co-founded by BAFTA Award-winning and Academy Award®-nominated actor Jude Law and creative partner Ben Jackson.
The investment will provide additional fire power to Riff Raff to increase key hires and acquire and develop premium IP. Together with its first look deal with American production company New Republic Pictures (NRP) inked in 2021, this investment will enable RRE to acquire highly sought-after material and attach premium writers across both sides of the Atlantic.
Riff Raff Entertainment produced Netflix limited series Black Rabbit adds a new cast member Morgan Spector.
WorkL is the home of the World’s Happiest Workplace List and the UK’s largest job marketplace
Harnessing the power of multiomics to transform genomic medicine
MIP Discovery is a novel affinity reagent company, commercialising various forms of Molecularly Imprinted Polymers.
Hinterview is an award-winning video platform for the recruitment sector.
Mo is an employee engagement platform, helping people build a more meaningful relationship with work
Laverock is a Gene Editing induced Gene Silencing platform.
Arctic Shores is leading the way to help employers build the diverse, successful workforce of tomorrow.
Optalitix adds value to insurers, and other financial institutions, with low code SaaS products, data analysis and sophisticated AI models.
Notify is a provider of digital workplace safety, wellbeing, environmental and governance compliance services.
Brouhaha is a production company with an extensive slate of projects.
Spectral has a 'DeepView' wound imaging system, aims to improve the accuracy and speed at which damaged tissue is identified and treated.
Invizius is a biotechnology company developing treatments to suppress unwanted innate immune responses
eConsult Health is the leading online consultation provider to the NHS for primary care
Arecor is a life sciences company focused on developing superior biopharmaceutical products via the application of its patented Arestat™ formulation technology platform
Censo Biotechnologies (Axol Bioscience) supply high quality adult human cells, especially live human neurons, created by stem cell technology, to many of the world’s biggest and best-known pharma companies and research institutions.
Home Team is a new TV and film production company
Maven is a leading media and entertainment development and production company, founded by experienced producers Celine Rattray and Trudie Styler.
Wazoku is an idea management company providing a customisable off-the-shelf platform to enterprise customers to manage innovation within an organisation
Rotageek uses cloud-based technology and automatic scheduling to help multi-site businesses manage and schedule staff
Essentia Analytics, a FinTech company, applying behavioural analytics to help professional asset managers make measurably better decisions
A UK-based production company co-founded by Oscar-winning actor Colin Firth and music industry veteran Ged Doherty
Evoterra brings traditional and renewable energy under one umbrella.
IPV provides digital asset management software to the global broadcast industry
A world leading provider of forensic financial solutions and services to protect organisational spend.
Wonderhood is the creative business founded by former Channel 4 CEO David Abraham and senior partners from the TV production and advertising sectors.
Quai Administration Services Limited is a digital administration company which provides an integrated, simplified administration platform for the high-volume personal savings industry.
Blu Wireless provides the technology required for microchips to process data at very high frequencies, for use in the roll-out of WiGig and 5G networks.
C4X Discovery is a drug discovery and development company
Oxford BioTherapeutics is a clinical stage oncology company committed to the discovery and development of novel therapies for various cancer types.
Weedingtech is a cleantech company focused on replacing toxic herbicides
Open Energy Market (‘OEM’), is an online trading platform for energy contracts for medium-large enterprises.
Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody and Moditope technology platforms
The investments referred to in this website are not suitable for all investors. Calculus Capital Limited is not able to give advice to prospective investors about the suitability of the investments. Prospective investors are recommended to seek specialist tax and financial advice before investing in the Calculus EIS Fund or Calculus VCT.
An investment into the Calculus EIS Fund of Calculus VCT may only be made on the basis of reading in full the information set out in the relevant Information Memorandum or prospectus.
When investing, your capital is at risk. The value of shares and income from them may go down as well as up and despite the tax relief you may not recover the amount originally invested. An investment in smaller and unquoted companies carries a higher risk than many other forms of investment. Shares in unquoted companies are not readily marketable. You should not invest in an EIS or VCT unless you can afford to lose some or all of your capital.
An EIS or VCT investment is only appropriate for investors with a medium to long term investment horizon; the timing and extent of realisation cannot be predicted and may extend beyond five years. It is not possible to allow a partial withdrawal of your investment. You may request a total withdrawal, but since many investments made will be in unquoted companies, this may not be possible. Withdrawal within three years for the EIS and five years for the VCT would lead to repayment of any tax reliefs received.
The tax benefits available depend upon your individual circumstances and these benefits may change dependent upon future legislation.
I have read and understood this important information
The investments referred to in this website are not suitable for all investors. Calculus Capital Limited is not able to give advice to prospective investors about the suitability of the investments. Prospective investors are recommended to seek specialist tax and financial advice before investing in the Calculus EIS Fund or Calculus VCT.
An investment into the Calculus EIS Fund of Calculus VCT may only be made on the basis of reading in full the information set out in the relevant Information Memorandum or prospectus.
When investing, your capital is at risk. The value of shares and income from them may go down as well as up and despite the tax relief you may not recover the amount originally invested. An investment in smaller and unquoted companies carries a higher risk than many other forms of investment. Shares in unquoted companies are not readily marketable. You should not invest in an EIS or VCT unless you can afford to lose some or all of your capital.
An EIS or VCT investment is only appropriate for investors with a medium to long term investment horizon; the timing and extent of realisation cannot be predicted and may extend beyond five years. It is not possible to allow a partial withdrawal of your investment. You may request a total withdrawal, but since many investments made will be in unquoted companies, this may not be possible. Withdrawal within three years for the EIS and five years for the VCT would lead to repayment of any tax reliefs received.
The tax benefits available depend upon your individual circumstances and these benefits may change dependent upon future legislation.
I have read and understood this important information